Pravin Dugel Sells 21,475 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL opened at $6.94 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $4.06 and a 12 month high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm has a market capitalization of $1.09 billion, a PE ratio of -5.26 and a beta of 1.22. The business’s fifty day moving average price is $7.95 and its 200 day moving average price is $8.92.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Creative Planning purchased a new stake in Ocular Therapeutix during the third quarter worth approximately $182,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ocular Therapeutix by 64.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 29,989 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 11,793 shares during the last quarter. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 0.4% in the 3rd quarter. Deltec Asset Management LLC now owns 2,600,073 shares of the biopharmaceutical company’s stock valued at $22,621,000 after buying an additional 9,808 shares in the last quarter. Finally, Rosalind Advisors Inc. grew its position in shares of Ocular Therapeutix by 18.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 885,000 shares of the biopharmaceutical company’s stock valued at $7,700,000 after buying an additional 135,000 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.